Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-label Study of PIPE-791 to Determine Brain and Lung Lysophosphatidic Acid Receptor 1 (LPA1) Occupancy, by [18F] PIPE-497 PET Imaging in Healthy Volunteers, Volunteers With Progressive Multiple Sclerosis, and Volunteers With Idiopathic Pulmonary Fibrosis

NCT06683612 is registered in ClinicalTrials.gov with Contineum Therapeutics as lead sponsor.

NCT NCT06683612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06683612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-label Study of PIPE-791 to Determine Brain and Lung Lysophosphatidic Acid Receptor 1 (LPA1) Occupancy, by [18F] PIPE-497 PET Imaging in Healthy Volunteers, Volunteers With Progressive Multiple Sclerosis, and Volunteers With Idiopathic Pulmonary Fibrosis
Lead sponsor
Contineum Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2024
Completion date
June 12, 2025
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, healthy volunteers, idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis (ipf), multiple sclerosis, multiple sclerosis, ms, multiple sclerosis, primary progressive, multiple sclerosis, progressive, multiple sclerosis, secondary progressive